New Insights on CACNA1C and Familial Epilepsy
Researchers studied a family affected by familial mesial temporal lobe epilepsy (FMTLE) to better understand how changes in a specific gene called CACNA1C can lead to this type of epilepsy.
This hub covers epilepsy genetics: how gene changes can contribute to seizures (often in children). We translate studies on testing, results like VUS, and what findings may change for care.
No. It’s common in pediatrics, but adults can benefit from genetic testing, too, especially with unclear diagnosis or family history.
Sometimes. For certain conditions, results can guide medication choice, diet therapies, or referral decisions.
It usually means “not enough evidence yet.” It shouldn’t be treated as a definite cause, but it can be reclassified over time.
Not necessarily. Testing can miss some variants, and new gene links are still being discovered.
Researchers studied a family affected by familial mesial temporal lobe epilepsy (FMTLE) to better understand how changes in a specific gene called CACNA1C can lead to this type of epilepsy.
This study looked at the occurrence of seizures and epilepsy in children diagnosed with leukodystrophies, which are rare brain disorders that affect the white matter of the brain.
Researchers studied wearable artificial intelligence (AI) technologies designed to help manage epilepsy, which affects around 50 million people worldwide.
Researchers studied a new tool called the iKETO-KNOW Questionnaire, which was designed to measure how much adult patients and caregivers know about the ketogenic diet therapy (KDT) for epilepsy.
Researchers studied the connection between Alzheimer’s disease (AD) and epilepsy, focusing on how these two conditions can affect each other.
Researchers studied a technique called transcranial focused ultrasound (tFUS), which is a non-invasive way to stimulate specific areas of the brain using sound waves.
Researchers studied neuron-specific enolase (NSE), an enzyme found in nerve cells, to see how it could help diagnose various neurological and psychiatric disorders.
A study was conducted in China, Japan, and South Korea to evaluate the effectiveness and safety of a medication called cenobamate for adults aged 18 to 70 who have uncontrolled focal seizures.
This study looked at epilepsy in people with a rare genetic condition called dentatorubral-pallidoluysian atrophy (DRPLA).